CIDEC-related familial partial lipodystrophy: A Patient Guide
At a Glance
CIDEC-related familial partial lipodystrophy (FPLD5) is a rare genetic disorder that changes fat storage, causing fat loss in the limbs and buttocks and fat buildup in the trunk or organs. Insulin resistance can lead to diabetes, high triglycerides, and fatty liver disease, but complications can be managed.
CIDEC-related familial partial lipodystrophy, also known as FPLD5, is a very rare genetic condition that changes how your body stores and manages energy. Because FPLD5 is so rare, individual features can vary significantly from person to person, and this guide does not replace a clinician’s individualized care plan.
At its core, this is a disorder of the fat cells, or adipocytes. In a healthy body, these cells act as storage tanks for fat, keeping it safely tucked away until the body needs it for fuel. In people with FPLD5, a mutation in the CIDEC gene disrupts the specialized machinery required to build these storage tanks, which can lead to a cascade of metabolic challenges [1].
The biological mechanism behind FPLD5 involves a failure of lipid droplet fusion. Normally, the CIDEC protein allows tiny droplets of fat within a cell to merge into one large, stable droplet [2]. Without a functional CIDEC protein, the fat remains fragmented into many tiny droplets that the cell cannot manage effectively. Because these cells can no longer provide safe storage, the body may lose fat in certain areas—most notably from the arms, legs, and buttocks—while compensating by storing fat in the face, neck, and trunk [1].
When the natural storage areas under the skin fail, the fat may be redirected into organs that were never meant to hold it, such as the liver and skeletal muscles. This redistribution, known as ectopic fat storage, can trigger severe insulin resistance. This resistance is a major driver behind the condition’s primary medical complications: type 2 diabetes, elevated levels of blood fats (hypertriglyceridemia), and fatty liver disease [1][3]. Not every person develops every listed problem, and severity varies.
While living with such a rare condition can be daunting, a diagnosis of FPLD5 provides a framework for your care. Although there is currently no cure for the underlying genetic mutation, the metabolic complications can be treated through a dedicated, coordinated approach. By working with your clinical team to focus on tailored nutrition and targeted medications, you can manage your risks and work to protect your long-term health [4].
In this guide
6 chapters
How Your Genes Affect Fat Storage (FPLD5)
Learn how CIDEC mutations cause FPLD5, disrupt fat-cell storage, and contribute to insulin resistance, high triglycerides, fatty liver, and ectopic fat.
Recognizing the Signs: Fat Distribution and Red Flags
Learn to recognize FPLD5 fat-loss patterns, insulin resistance signs, eruptive xanthomas, and emergency symptoms linked to high triglycerides and pancreatitis.
Getting Answers: The Path to a Diagnosis
Learn how Familial Partial Lipodystrophy Type 5 (FPLD5) is diagnosed, including clinical clues, fat-distribution imaging, and CIDEC genetic testing results.
Managing the Metabolic Burden: Standard of Care
Learn how FPLD5 treatment manages high blood sugar, triglycerides, fatty liver risk, and pancreatitis with diet, medicines, and specialist care and follow-up.
Staying Ahead: Long-Term Monitoring and Health Checks
Learn how to monitor familial partial lipodystrophy (FPLD5), including blood sugar, liver, kidney, and heart checks, OGTTs, FibroScan, and pregnancy planning.
Assembling Your Team: Specialized Care and Support
Learn how to build a Familial Partial Lipodystrophy Type 5 care team, choose specialists, prepare for visits, coordinate monitoring, and find emotional support.
Common questions in this guide
What is CIDEC-related familial partial lipodystrophy (FPLD5)?
Why does FPLD5 cause fat loss in some areas and fat gain in others?
What health complications can FPLD5 cause?
Can CIDEC-related familial partial lipodystrophy be cured?
Why can someone with FPLD5 look lean but still have metabolic problems?
How should people with FPLD5 be monitored?
Get notified when new evidence is published on CIDEC-related familial partial lipodystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (4)
- 1
Novel Homozygous Variants in CIDEC and WRN in a Young Female with Lipodystrophy and Thyroid Cancer.
Patni N, Xing C, Huang CY, et al.
International journal of molecular sciences 2026; (27(2)) doi:10.3390/ijms27020646.
PMID: 41596298 - 2
Human CIDEC transgene improves lipid metabolism and protects against high-fat diet-induced glucose intolerance in mice.
Gupta A, Balakrishnan B, Karki S, et al.
The Journal of biological chemistry 2022; (298(9)):102347 doi:10.1016/j.jbc.2022.102347.
PMID: 35963433 - 3
When Adipose Tissue Lets You Down: Understanding the Functions of Genes Disrupted in Lipodystrophy.
Rochford JJ
Diabetes 2022; (71(4)):589-598 doi:10.2337/dbi21-0006.
PMID: 35316838 - 4
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.
PMID: 27710244
This page is for informational purposes only and does not constitute medical advice or replace an individualized care plan. An endocrinology or genetics team can help interpret your FPLD5 risks and guide treatment.